RECOMBINANT HUMAN INSULIN-LIKE-GROWTH-FACTOR AS A THERAPEUTIC AGENT FOR SEVERE INSULIN-RESISTANCE AND TYPE-II DIABETES-MELLITUS

Recombinant human insulin-like growth factor I (rhIGF-I) shares many p hysiological properties with its structural homolog insulin. Studies i n normal humans have confirmed the hypoglycemic potential of exogenous rhIGF-I and have provided a rationale for the testing of rhIGF-I as a potential therapy in states of severe insulin resistance and in type II diabetes mellitus. These studies have demonstrated that rhIGP-I can improve hyperglycemia, hyperinsulinemia and insulin sensitivity in su bjects with severe insulin resistance and that it can improve glycemic control and insulin sensitivity in patients with type II diabetes mel litus. Data are accruing that rhIGF-I can also improve hypertriglyceri demia associated with these insulin resistant states. While early stud ies have revealed significant side effects of rhIGF-I at doses greater than 90 mu g/kg b.i.d., more recent preliminary data suggest that eff icacious doses with good patient tolerance can be identified.